ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Goy on Future Agents Against Lymphoma

Andre Goy, MD
Published: Wednesday, Mar 26, 2014

Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses emerging agents in lymphoma.

Goy says there are many small molecule agents that will continue to change the landscape of the treatment of lymphoma but research into CAR technology in large-cell lymphoma is striking. A trial of this technology has shown that 8 out of 9 large-cell lymphoma patients were primary refractory or refractory to chemotherapy responded to treatment.

Manipulating the immune system and building up on PD-1 are critical to the future of lymphoma, Goy says.
 
Andre Goy, MD, MS, chairman, director, and chief of the Lymphoma Division at the John Theurer Cancer Center, discusses emerging agents in lymphoma.

Goy says there are many small molecule agents that will continue to change the landscape of the treatment of lymphoma but research into CAR technology in large-cell lymphoma is striking. A trial of this technology has shown that 8 out of 9 large-cell lymphoma patients were primary refractory or refractory to chemotherapy responded to treatment.

Manipulating the immune system and building up on PD-1 are critical to the future of lymphoma, Goy says.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x